Citigroup
AVBP icon

Citigroup’s ArriVent BioPharma AVBP Stock Holding History

Citigroup’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
41,265
+33,830
+455% +$998K ﹤0.01% 3179
2026
Q1 		$172K Sell
7,435
-658
-8% -$14.9K ﹤0.01% 4068
2025
Q4 		$163K Sell
8,093
-1,944
-19% -$40.5K ﹤0.01% 4089
2025
Q3 		$185K Sell
10,037
-11,530
-53% -$227K ﹤0.01% 4023
2025
Q2 		$470K Sell
21,567
-12,602
-37% -$262K ﹤0.01% 3665
2025
Q1 		$632K Buy
34,169
+48
+0.1% +$1.18K ﹤0.01% 3548
2024
Q4 		$909K Buy
34,121
+13,721
+67% +$394K ﹤0.01% 3431
2024
Q3 		$479K Buy
20,400
+18,237
+843% +$414K ﹤0.01% 3757
2024
Q2 		$40.1K Buy
2,163
+422
+24% +$7.53K ﹤0.01% 4713
2024
Q1 		$31.1K Buy
+1,741
New +$35.1K ﹤0.01% 4879

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's AVBP Position: Q2 2026 in Review

Citigroup increased its ArriVent BioPharma (AVBP) stake by 455% in Q2 2026, buying an estimated $998K and bringing the position to 41,265 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3179.

Citigroup first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Citigroup held 41,265 shares of ArriVent BioPharma worth $1.43M as of Q2 2026.
  • Citigroup bought 33,830 ArriVent BioPharma shares in Q2 2026, an estimated $998K.
  • ArriVent BioPharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3179 holding.
  • Citigroup first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.